Patient description: The patient is a 17-year-old boy complaining of severe migratory pain in the right lower quadrant of his abdomen that started four days ago. The pain is accompanied by nausea and vomiting. He was febrile with tenderness, rebound tenderness and guarding on palpation. His WBC was elevated with dominant neutrophils. CT scan showed evidence of acute perforated appendicitis with free fluid in the pelvis. Diagnostic laparoscopy revealed phlegmon with no other abdominal abnormalities. He is now a candidate for emergent laparoscopic appendectomy under general anesthesia.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Solid Tumor Colorectal Cancer (Inclusion for the completed initial dose escalation phase using PF-02341066/PD-0325901 are listed in Appendix 7.) All patients Age ≥ 16 years (>18 years in France) ECOG performance status 0-1 (Appendix 1) Adequate respiratory function on clinical assessment Left ventricular ejection fraction (LVEF) ≥ 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram┼ Able to give informed consent prior to any screening procedures being performed and be capable of complying with the protocol and its requirements Haematological and biochemical indices within the ranges shown below Haemoglobin (Hb) ≥ 9g/dl (transfusion to achieve this allowed ) Neutrophils ≥ 1,500/μl Platelet count ≥ 100,000/μl  for the completed initial dose escalation phase using PF-02341066/PD-0325901 are listed in Appendix 7.) All patients Unstable ischaemic heart disease, cardiac dysrhythmias, coronary/peripheral artery bypass graft or cerebrovascular accident within 6 months prior to starting treatment Uncontrolled arterial hypertension despite medical treatment Ongoing congestive heart failure or cardiac dysrhythmias of NCI CTCAE Grade ≥2 or uncontrolled atrial fibrillation History of extensive disseminated/bilateral or known presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease (ILD), obliterative bronchiolitis, and pulmonary fibrosis. A history of prior radiation pneumonitis is allowed Any active central nervous system (CNS) lesion (i.e., those with radiographically unstable, symptomatic lesions) and/or leptomeningeal metastases. However, patients treated with stereotactic radiotherapy or surgery are eligible if the patient remained without evidence of CNS disease progression ≥ 3 months. Patients must be off corticosteroid therapy for ≥ 3 weeks Patients who have neuromuscular disorders that are associated with elevated CK (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy) Patients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment. NB: Muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided while on Binimetinib treatment Spinal cord compression unless treated with the patient attaining good pain control and stable or recovered neurologic function Carcinomatous meningitis or leptomeningeal disease